Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lipella Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LIPO
Nasdaq
8731
https://lipella.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lipella Pharmaceuticals Inc
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
- Apr 17th, 2024 12:00 pm
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
- Apr 5th, 2024 12:00 pm
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
- Apr 3rd, 2024 12:00 pm
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease
- Mar 7th, 2024 8:23 pm
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
- Mar 5th, 2024 1:00 pm
Lipella Pharmaceuticals Full Year 2023 Earnings: US$0.77 loss per share (vs US$0.64 loss in FY 2022)
- Mar 1st, 2024 11:18 am
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
- Feb 20th, 2024 1:00 pm
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
- Dec 20th, 2023 1:00 pm
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
- Nov 10th, 2023 1:00 pm
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Oct 25th, 2023 8:05 pm
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Oct 24th, 2023 12:00 pm
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference
- Oct 23rd, 2023 12:30 pm
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
- Oct 20th, 2023 12:00 pm
Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology
- Sep 21st, 2023 12:30 pm
Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders
- Jun 13th, 2023 12:30 pm
Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
- May 15th, 2023 1:15 pm
Lipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022)
- May 14th, 2023 12:12 pm
Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting
- May 1st, 2023 12:30 pm
Scroll